Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Pasi A. Jänne, Michael Thomas et al.|New England Journal of Medicine|2013Cited by 3.4k
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung CancerGiorgio V. Scagliotti, Nasser H. Hanna, Silvia Novello et al.|Journal of Clinical Oncology|2010Cited by 454
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancerGiannis Mountzios, Petros Christopoulos, Epaminontas Samantas et al.|ESMO Open|2021Cited by 93
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerByoung Chul Cho, Alexander I. Spira, Enriqueta Felip et al.|Future Oncology|2021Cited by 93
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C. Bendell, Michael Thomas, Helge Bischoff et al.|Investigational New Drugs|2019Cited by 30